Keybanc Initiates Coverage of Guardian Pharmacy Services at Overweight
Fintel reports that on September 23, 2026, Keybanc initiated coverage of Guardian Pharmacy Services (NYSE:GRDN) with a Overweight recommendation.
Prior to this action, the stock closed at $44.67 on September 22, 2026. This latest close reflects a one-week price change of -6.94% from a baseline close of $48.00 on September 15, 2026. Over a longer one-month timeframe, the stock registered a price change of +17.77% from a baseline close of $37.93 on August 21, 2026.
In terms of broader analyst sentiment, the current consensus target mean for the stock was $49.81 as of September 15, 2026, which is identical to the prior consensus target mean of $49.81 recorded on August 31, 2026, representing a revision of 0.00%. The current consensus target median stands at $50.49 as of September 15, 2026, implying a target change of +11.51%.
For the recommendation period of September 1, 2026, the aggregate analyst recommendations consisted of 6 strong buy, 5 buy, 1 hold, 0 sell, and 0 strong sell ratings. This distribution yields 91.7% positive, 8.3% hold, and 0.0% negative recommendations out of 12 total. These figures remain unchanged from the prior recommendation period of August 1, 2026, which also reported 6 strong buy, 5 buy, 1 hold, 0 sell, and 0 strong sell ratings, totaling 12 recommendations with 91.7% positive, 8.3% hold, and 0.0% negative shares.
In its latest quarterly earnings report on August 6, 2026, Guardian Pharmacy Services reported an actual EPS of 0.34, surpassing the estimated EPS of 0.2795, which is a surprise of +21.65%. The company recorded actual revenue of $351,768,000.00, compared to the estimated revenue of $346,845,492.00. Additionally, on September 21, 2026, Truist Securities maintained its Buy rating on the company, keeping its rating at Buy.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 23, 2026 | Keybanc | Overweight | initiated coverage | |
| September 21, 2026 | Truist Securities | Buy | Buy | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.